26 citations
,
January 1992 in “Carcinogenesis” TPA strongly increases ODC activity in certain skin cells, potentially aiding tumor growth.
January 2018 in “Springer eBooks” PDE inhibitors, especially PDE4 inhibitors like apremilast, are effective for certain inflammatory skin conditions but have side effects and can be costly.
July 2025 in “Pharmaceutics” Recombinant Human Annexin A5 may help treat localized scleroderma by reducing skin thickening and inflammation.
January 2022 in “Social Science Research Network” Potassium channel modulators mostly increase the activity of rat whisker mechanoreceptors.
Eriocitrin and silymarin might be effective for hair loss treatment and need more research.
Hit15 shows promise as a COVID-19 treatment by reducing virus infection and inflammation.
May 2024 in “Brain disorders” Agmatine may help reduce seizures linked to hormone changes in female rats.
January 2025 in “Drug repurposing” New drug uses show promise but need more research.
21 citations
,
April 2016 in “International Journal of Oncology” GnRH treatment can reduce breast cancer cell invasion.
April 2017 in “Journal of Investigative Dermatology” Triptolide effectively and safely reduces actinic keratosis lesions in mice.
4 citations
,
May 2019 in “The World Journal of Men's Health” Taking 5 alpha reductase inhibitor medication slightly increases the risk of depression, especially as you get older.
147 citations
,
June 2011 in “New England journal of medicine/The New England journal of medicine” 5α-reductase inhibitors may prevent prostate cancer but could also raise the risk of more severe cancers.
1 citations
,
January 2022 in “Journal of Pharmaceutical Sciences” The new skin cream with FOL-005 safely promotes hair growth and is stable and user-friendly.
16 citations
,
September 1999 in “Journal of Investigative Dermatology Symposium Proceedings” Marine sponges from Tabuhan Island can inhibit enzymes linked to Alzheimer's and hair loss.
January 2011 in “Medical Recapitulate” 5α-reductase enzyme affects hormone levels, influencing conditions like acne and hair loss.
49 citations
,
April 1997 in “Human reproduction” Hormone therapy for excessive hair growth is as good with GnRHa as with high-dose CPA, but GnRHa has longer-lasting results.
November 2025 in “Russian Journal of Oncology” Modifying steroidal inhibitors shows promise for developing new cancer treatments.
January 2026 in “Figshare” Finasteride can cause melasma, especially in people with darker skin.
22 citations
,
September 2002 in “Der Urologe” Alpha1-blockers effectively improve urinary symptoms in BPH, with alfuzosin and tamsulosin having fewer side effects.
May 2024 in “Journal of cosmetic dermatology” Heat-treated Limosilactobacillus fermentum with menthol, salicylic acid, and panthenol promotes hair growth and balances scalp microbiome in people with androgenetic alopecia.
20 citations
,
September 2005 in “Endocrinology” Certain changes to the B-ring of androgen receptor ligands can increase their effectiveness for potential treatments of muscle and bone conditions.
December 2025 in “International Neurourology Journal” Alpha-blockers and 5-alpha reductase inhibitors don't significantly increase dementia risk.
6 citations
,
July 2018 in “Scientific Reports” Methamphetamine affects gene expression in rat whisker follicles, with key genes linked to addiction.
October 2025 in “Biomedicines” Terminalia chebula fruit extract helps hair growth by reducing DHT and boosting hair cell activity.
9 citations
,
July 2011 in “The Journal of Sexual Medicine” Hair loss drugs like finasteride may cause lasting sexual and mood side effects, and more research is needed to understand these risks.
40 citations
,
April 1999 in “Drugs” Finasteride treats enlarged prostate, improves urinary flow, but may cause sexual side effects.
April 2026 in “International Journal of Drug Delivery Technology” Topical prostaglandin analogues may improve hair density in androgenetic alopecia, but more research is needed.
1 citations
,
October 2024 in “JCEM Case Reports” 5α-reductase deficiency can cause ambiguous genitalia and gender dysphoria, treatable with testosterone.
April 2026 in “Therapeutic Advances in Drug Safety” Finasteride is high-risk for cognitive disorders, while Carbidopa/Levodopa, Topiramate, and Clonazepam are moderate-risk.